GalbraithWight CEO, Colin Wight talks about our new service Bio-MAP Europe: the strategic market access plan ‘in a box’ for Biotech

Are you a SME Biotech who is in the clinic, with funding, a European launch to plan for in the next 3-4 years and concerned about how to navigate complex pricing and reimbursement approval across the many European countries? I am proud to announce the launch of a new service specifically designed for you; Bio-MAP Europe.